4cr9: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design== | ==Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design== | ||
<StructureSection load='4cr9' size='340' side='right' caption='[[4cr9]], [[Resolution|resolution]] 1.70Å' scene=''> | <StructureSection load='4cr9' size='340' side='right'caption='[[4cr9]], [[Resolution|resolution]] 1.70Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4cr9]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4CR9 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4CR9 FirstGlance]. <br> | <table><tr><td colspan='2'>[[4cr9]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4CR9 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4CR9 FirstGlance]. <br> | ||
| Line 31: | Line 31: | ||
[[Category: Coagulation factor XIa]] | [[Category: Coagulation factor XIa]] | ||
[[Category: Human]] | [[Category: Human]] | ||
[[Category: Large Structures]] | |||
[[Category: Akkaya, S]] | [[Category: Akkaya, S]] | ||
[[Category: Beisel, H G]] | [[Category: Beisel, H G]] | ||